

Supplementary Table S1. Incidence rates of prescriptions for each 6-month period after TNFi initiation among axSpA patients.

	Number of prescriptions (NP)	Patient-years	Incidence rate, events/person years (CI 95%)	Incidence rate ratio (95% CI)
Anti-infectives				
After TNFi				
SP1	275	184.52	1.49 (1.32 - 1.68)	Reference
SP2	262	178.17	1.47 (1.30 - 1.66)	0.99 (0.83-1.17)
SP3	233	175.40	1.33 (1.16 - 1.51)	0.89 (0.74-1.07)
SP4	260	181.38	1.43 (1.26 - 1.62)	0.96 (0.81-1.14)
Antibiotics				
After TNFi				
SP1	254	184.52	1.38 (1.21-1.56)	Reference
SP2	232	178.17	1.30 (1.14-1.48)	0.95 (0.79-1.13)
SP3	210	175.40	1.20 (1.04-1.37)	0.87 (0.72-1.04)
SP4	232	181.38	1.28 (1.12-1.45)	0.93 (0.77-1.11)
Antivirals				
After TNFi				
SP1	9	184.52	0.05 (0.022-0.09)	Reference
SP2	12	178.17	0.07 (0.035-0.12)	1.38 (0.53-3.71)
SP3	11	175.40	0.06 (0.03-0.112)	1.29 (0.48-4.3.51)
SP4	21	181.38	0.12 (0.07-0.18)	2.37 (1.04-5.88)*
Antimycotics				
After TNFi				
SP1	12	184.52	0.07 (0.03-0.11)	Reference
SP2	18	178.17	0.10 (0.06-0.16)	1.55 (0.71-3.53)
SP3	12	175.40	0.07 (0.04-0.12)	1.05 (0.43- 2.56)
SP4	7	181.38	0.04 (0.16 - 0.8)	0.59 (0.20-1.63)

axSpA: axial spondyloarthritis; TNFi: tumour necrosis factor α inhibitor; CI: confidence interval; NP: number of prescriptions; SP1: subperiod 1; SP2: subperiod 2; SP3: subperiod 3; SP4: subperiod 4.

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Supplementary Table S2. Incidence rate of prescriptions for males and females with axSpA before and after TNFi therapy.

	Number of prescriptions (NP)		Patient-years		Incidence rate, events/person years (CI 95%)		
	Female	Male	Female	Male	Female	Male	Incidence rate ratio (95% CI)
Anti-infectives							
Before TNFi	367	467	250.52	495.12	1.46 (1.32-1.62)	0.94 (0.86-1.03)	0.64 (0.56-0.74) ***
After TNFi	447	583	238.07	481.39	1.88 (1.71-2.06)	1.21 (1.1-1.31)	0.64 (0.57- 0.73) ***
Incidence rate ratio (95% CI)					1.28 (1.11-1.48) ***	1.28 (1.12-1.45) ***	
Antibiotics							
Before TNFi	332	445	250.52	495.12	1.33 (1.19-1.48)	0.90 (0.82-0.98)	0.68 (0.59-0.78) ***
After TNFi	394	534	238.07	481.39	1.65 (1.5-1.83)	1.11 (1.02-1.21)	0.67 (0.59-0.77) ***
Incidence rate ratio (95% CI)					1.25 (1.08-1.45) **	1.23 (1.09-1.40) **	
Antivirals							
Before TNFi	13	6	250.52	495.12	0.05 (0.03-0.09)	0.01 (0.004-0.026)	0.23 (0.07-0.66) **
After TNFi	18	35	238.07	481.39	0.08 (0.04-0.1)	0.07 (0.06-0.1)	0.96 (0.53-1.80)
Incidence rate ratio (95% CI)					1.45 (0.67-3.2)	6.00 (2.5-17.5) ***	
Antimycotics							
Before TNFi	22	16	250.52	495.12	0.09 (0.06-0.1)	0.032 (0.02-0.05)	0.37 (0.18-0.73) **
After TNFi	35	14	238.07	481.39	0.15 (0.10-0.2)	0.03 (0.02-0.05)	0.2 (0.098-0.38) ***
Incidence rate ratio (95% CI)					1.67 (0.95-3)	0.90 (0.41-1.97)	

TNFi: tumour necrosis factor α inhibitor; CI: confidence interval; NP: number of prescriptions.

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.